{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:09:58Z","timestamp":1791252598836,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,11,4]],"date-time":"2004-11-04T00:00:00Z","timestamp":1099526400000},"content-version":"vor","delay-in-days":2256,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1998,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The antidyskinetic potential of the glutamate NMDA receptor channel blocker amantadine was evaluated in four levodopa\u2010primed parkinsonian monkeys using two different regimens (1.25 or 2.5 mg\/kg administered subcutaneously twice daily for 3\u20136 days). When administered with a relatively low dose of levodopa, amantadine produced a near\u2010total suppression of choreiform dyskinesias and a substantial reduction in dystonic dyskinesias at the expense of a significant reduction in antiparkinsonian response. With a high dose of levodopa, amantadine had a smaller but still significant effect on dyskinesias without altering the antiparkinsonian response. These results lend support to the view that glutamate receptormediated mechanisms contribute to levodopa\u2010induced dyskinesias. They also suggest that amantadine could alleviate such complications in parkinsonian patients, especially with careful dose optimization.<\/jats:p>","DOI":"10.1002\/mds.870130507","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T09:49:30Z","timestamp":1104486570000},"page":"798-802","source":"Crossref","is-referenced-by-count":165,"title":["Amantadine reduces levodopa\u2010induced dyskinesias in parkinsonian monkeys"],"prefix":"10.1002","volume":"13","author":[{"given":"Pierre J.","family":"Blanchet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Konitsiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,11,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)00924-3"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390505"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(91)90113-V"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)39350-X","article-title":"Differential effect of selective D\u20101 and D\u20102 dopamine receptor agonists on levodopa\u2010induced dyskinesia in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010exposed monkeys","volume":"267","author":"Blanchet P","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.3.711"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110516"},{"key":"e_1_2_1_8_2","first-page":"A328","article-title":"Amantadine ameliorates levodopa induced dyskinesia [Abstract]","volume":"48","author":"Rajput AH","year":"1997","journal-title":"Neurology"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199310000-00004"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(73)90132-5"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15736.x"},{"key":"e_1_2_1_12_2","first-page":"143","volume-title":"Therapy of Parkinson's Disease","author":"Kulisevsky J","year":"1990"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430290309"},{"key":"e_1_2_1_14_2","first-page":"21","article-title":"Studies on the mechanism of action of the antiparkinsonian drugs memantine and amantadine: no evidence for direct dopaminomimetic or antimuscarinic properties","volume":"320","author":"Jackisch R","year":"1992","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(85)90564-3"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90066-F"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)00355-8"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(89)90372-9"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)94802-5"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90694-I"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870130507","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870130507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:57:36Z","timestamp":1760957856000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870130507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,9]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,9]]}},"alternative-id":["10.1002\/mds.870130507"],"URL":"https:\/\/doi.org\/10.1002\/mds.870130507","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,9]]}}}